-- Neurosom has received a patent allowance for the Sleep WISP™, which secures several new aspects of unique IP for the company. The recently discovered glymphatic system of the central nervous system clears toxic metabolic waste by pushing cerebrospinal fluid (CSF) through the brain during sleep. Scientists have found that greater glymphatic clearance may be a breakthrough in preventing neurodegenerative diseases of the brain like Alzheimer’s and Parkinson’s disease.
The Sleep WISP™—a comfortable headband designed for at-home use—is now patented to register a Glymphatic Clearance Capacity, a measure of the changes in brain fluid content, extracellular space, and glymphatic waste clearance. Additionally, the patent covers an improvement in glymphatic flow through the Sleep WISP™ stimulation, which reduces EEG impedance and increases extracellular space in the brain, specifically by finding the optimal sleep window for stimulation.
“This patent is another significant milestone for Neurosom™,” says CEO Viral Sheth. “We are developing the Sleep WISP™ to be both a sophisticated diagnostic and therapeutic tool in the next generation of brain care.”
As many scientists push to uncover the early signs of cognitive decline that lead to neurodegenerative disease, Neurosom™ believes that earlier screening for signs of memory impairment or cognitive changes could enable more effective intervention and better outcomes for many people affected by Alzheimer’s or Parkinson’s disease.
“At Neurosom™, we are working to give the healthcare community a continuum of care for the brain that revolutionizes Neuro Care. Much like oncology has evolved at light speed with earlier screenings and interventions, we believe the same approach can be applied with neurodiagnostic tools.”
“With the addition of AI software into our system, we’re able to use computational modeling to measure the conductivity of head tissues, and we use a skin-path-correction algorithm,” says Sheth. “Basically, the technology has grown exponentially in the last few years, giving us new detection tools.”
When asked about how the new patent will affect future plans for the Sleep WISP™ in 2026, Sheth comments, “We have these measures in our current clinical trial and will analyze the glymphatic clearance in relation to MCI and the response to sleep therapy.”
Other standout features of the patent include:
• Integrating Skull Current Flow Analysis for Safety Monitoring
• Optimizing and monitoring Foramen Magnum Current Flow
The placement of the Sleep WISP™ electrodes at the base of the neck is unique to Neurosom™ and provides the ability to use less current for stimulation while optimizing efficacy and safety monitoring.
About Neurosom™
Neurosom™ is a medical device company dedicated to reducing dementia risk and improving brain health by optimizing deep and REM sleep. Founded in 2021, the company developed the innovative, wearable Sleep WISP™ device, which measures EEG sleep cycles at home and delivers personalized, painless electrical stimulation using AI-powered, FDA-cleared software. This approach extends and enhances deep and REM sleep—the sleep stages that enable the brain to clear harmful plaques associated with neurodegenerative diseases.
Headquartered in Eugene, Oregon, Neurosom™ is committed to advancing the future of sleep and brain health care. For more information, visit https://neurosom.net
Contact Info:
Name: Corin Tucker
Email: Send Email
Organization: Neurosom™
Website: https://neurosom.net
Release ID: 89182271
If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.
